ClinicalTrials.gg
CompletedNCT05570539Updated May 18, 2025

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

A Phase 1 interventional study of BLU-5937 IR and BLU-5937 ER in Cough and Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.

Enrollment
8th of 10
30 · median 44
Started
2022
with 2 others
Phase 1
7 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
8 of 10
Bellus Health Inc. - a GSK company

Among the 10 studies testing BLU-5937 in Cough, this one is the 8th largest by enrollment, is one of 3 that started in 2022, is one of 7 in phase 1, and was the 2nd registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About BLU-5937

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing BLU-5937 in Cough, or all of them as a file.
02

Study summary

This is a Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects

03

Conditions studied

  • Cough
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, renal, hepatic, metabolic, dermatological, respiratory, GI, neurological, endocrine, haematological, immunological or psychiatric disorder, as judged by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Immediate Release formulation

    IR Formulation

    Drug: BLU-5937 IR

  • Experimental
    Extended Release formulation

    ER formulation

    Drug: BLU-5937 ER

Interventions

  • Each subject will receive two single and multiple administrations of Immediate Release reference formulation

  • Each subject will receive single and multiple oral administrations of Extended Release formulation

06

What researchers measure

Primary outcomes

  1. Measurement of the maximum observed plasma drug concentration (Cmax)

    To assess the comparison between Cmax following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.

    Time frame: Pre dose up to 36 hours post-dose

  2. Measurement of the minimum observed plasma drug concentration (Cmin)

    To assess the comparison between Cmin following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.

    Time frame: Pre dose up to 36 hours post-dose

  3. Measurement of the area under the plasma drug concentration by time curve AUC

    To assess the comparison between AUC following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.

    Time frame: Pre dose up to 36 hours post-dose

  4. Measurement of the observed plasma drug concentration 24 hours post-dose (C24)

    To assess the comparison between C24 following administration of an Extended Release tablet formulation and an Immediate Release reference formulation.

    Time frame: 24 hours post-dose

07

Study locations

1 site
  • GSK Investigational Site
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2024, 18 months.

Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Oct 7, 2022
Primary completionActual
May 2, 2024
CompletionActual
Jul 1, 2024
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05570539
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Oct 7, 2022
Primary completion
May 2, 2024
Completion
Jul 1, 2024
Last update
May 18, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion